<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00870311</url>
  </required_header>
  <id_info>
    <org_study_id>H12-48-95</org_study_id>
    <secondary_id>NIMH (MH159107)</secondary_id>
    <nct_id>NCT00870311</nct_id>
  </id_info>
  <brief_title>Investigation of Lithium on Signal Transduction, Gene Expression and Brain Myo-Inositol Levels in Manic Patients</brief_title>
  <official_title>Investigation of Lithium on Signal Transduction, Gene Expression and Brain Myo-Inositol Levels in Manic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wayne State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Wayne State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the effects of Lithium treatment on signal transduction pathways,
      gene expression and brain neurochemistry and structure in patients with Bipolar disorder. It
      is hypothesized that specific changes in these markers will correlate with lithium treatment
      responsiveness.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study investigates the effects of blinded lithium treatment longitudinally in patients
      with bipolar disorder. At baseline and at multiple time points following the initiation of
      lithium treatment over 4 or more weeks, measures of signal transduction pathways, gene
      expression and brain neurochemistry and structure were obtained. It is hypothesized that
      modulation of these measures will be predictive of lithium treatment responsiveness.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 1996</start_date>
  <completion_date type="Actual">April 2004</completion_date>
  <primary_completion_date type="Actual">April 2004</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Brain myo-inositol levels</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Signal transduction pathway measures</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gene expression levels</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain volume</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>Blinded Lithium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bipolar Disorder patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lithium Carbonate</intervention_name>
    <description>300mg PO, three times daily with dose titrated to obtain a therapeutic plasma level of 0.8 to 1.2meq/L) over the first week of treatment. Total duration is a minimum of 3 weeks. Medication is dispensed in the form of blinded research capsules.</description>
    <arm_group_label>Blinded Lithium</arm_group_label>
    <other_name>Eskalith</other_name>
    <other_name>Lithonate</other_name>
    <other_name>Lithane</other_name>
    <other_name>Lithotabs</other_name>
    <other_name>Lithobid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meet diagnostic criteria for Bipolar Mood Disorder determined by DSM-IV (SCID)

        Exclusion Criteria:

          -  Meeting criteria for any other DSM-IV axis I disorder

          -  Psychoactive substance abuse or dependence within the past 1 year

          -  Medical conditions placing patients at increased risk for lithium treatment (including
             renal disease, hepatic disease, hematological disease)

          -  Devices/implants or conditions which preclude MRI investigation (including cardiac
             pacemaker/ICD, aneurysm clips, neurostimulator device, metallic fragments in or near
             the eye,claustrophobia)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Husseini K Manji, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wayne State University, National Institute of Mental Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Debra A Glitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wayne State University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gregory J Moore, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wayne State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wayne State University School of Medicine</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Chen G, Hasanat KA, Bebchuk JM, Moore GJ, Glitz D, Manji HK. Regulation of signal transduction pathways and gene expression by mood stabilizers and antidepressants. Psychosom Med. 1999 Sep-Oct;61(5):599-617. Review.</citation>
    <PMID>10511011</PMID>
  </results_reference>
  <results_reference>
    <citation>Moore GJ, Bebchuk JM, Parrish JK, Faulk MW, Arfken CL, Strahl-Bevacqua J, Manji HK. Temporal dissociation between lithium-induced changes in frontal lobe myo-inositol and clinical response in manic-depressive illness. Am J Psychiatry. 1999 Dec;156(12):1902-8.</citation>
    <PMID>10588403</PMID>
  </results_reference>
  <results_reference>
    <citation>Moore GJ, Bebchuk JM, Hasanat K, Chen G, Seraji-Bozorgzad N, Wilds IB, Faulk MW, Koch S, Glitz DA, Jolkovsky L, Manji HK. Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2's neurotrophic effects? Biol Psychiatry. 2000 Jul 1;48(1):1-8.</citation>
    <PMID>10913502</PMID>
  </results_reference>
  <results_reference>
    <citation>Moore GJ, Bebchuk JM, Wilds IB, Chen G, Manji HK. Lithium-induced increase in human brain grey matter. Lancet. 2000 Oct 7;356(9237):1241-2. Erratum in: Lancet 2000 Dec 16;356(9247):2104. Menji HK [corrected to Manji HK].</citation>
    <PMID>11072948</PMID>
  </results_reference>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2009</study_first_submitted>
  <study_first_submitted_qc>March 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2009</study_first_posted>
  <last_update_submitted>March 25, 2009</last_update_submitted>
  <last_update_submitted_qc>March 25, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 27, 2009</last_update_posted>
  <responsible_party>
    <name_title>Husseini K. Manji, MD, F.R.C.P.C.</name_title>
    <organization>Wayne State University and National Institute of Mental Health</organization>
  </responsible_party>
  <keyword>Lithium</keyword>
  <keyword>Neuroprotection</keyword>
  <keyword>Neurotrophic</keyword>
  <keyword>bcl2</keyword>
  <keyword>gsk3</keyword>
  <keyword>pkc</keyword>
  <keyword>MRI</keyword>
  <keyword>myoinositol</keyword>
  <keyword>MRS</keyword>
  <keyword>Alzheimers Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lithium Carbonate</mesh_term>
    <mesh_term>Inositol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

